| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue from customers | 741 | 965 | - | 19 |
| Research and development | 23,937 | 13,976 | 14,502 | 16,774 |
| General and administrative | 5,165 | 5,556 | 5,052 | 4,626 |
| Total operating expenses | 29,102 | 19,532 | 19,554 | 21,400 |
| Revenue from customers | - | - | 311 | 1,250 |
| Loss from operations | -28,361 | -18,567 | -19,243 | -20,131 |
| Interest and other income, net | 1,085 | 1,207 | 880 | 963 |
| Change in fair value of 2023 common warrants | 4,205 | -1,682 | -61,494 | - |
| Loss before income tax | -31,481 | -15,678 | 43,131 | -19,168 |
| Income tax provision | 56 | 185 | 43 | 91 |
| Net loss | -31,537 | -15,863 | 43,088 | -19,259 |
| Unrealized gain on available-for-sale securities | 35 | -27 | -4 | 83 |
| Other comprehensive gain | 35 | -27 | -4 | 83 |
| Comprehensive loss | -31,502 | -15,890 | 43,084 | -19,176 |
| Earnings per share, basic, total | -3.04 | -1.53 | 5.12 | -3.07 |
| Earnings per share, diluted, total | -3.04 | -1.53 | -2.11 | -3.07 |
| Weighted average number of shares outstanding, basic, total | 10,369,535 | 10,351,120 | 8,408,481 | 6,272,291 |
| Weighted average shares of common stock, diluted | 10,369,535 | 10,351,120 | 8,709,693 | 6,272,291 |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)